001     884114
005     20210130005833.0
024 7 _ |a 10.1128/JVI.01338-20
|2 doi
024 7 _ |a 0022-538X
|2 ISSN
024 7 _ |a 1070-6321
|2 ISSN
024 7 _ |a 1098-5514
|2 ISSN
024 7 _ |a 2128/26249
|2 Handle
024 7 _ |a 32907979
|2 pmid
024 7 _ |a WOS:000595866900008
|2 WOS
037 _ _ |a FZJ-2020-03101
082 _ _ |a 610
100 1 _ |a Twizerimana, Augustin Penda
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Cell type-dependent escape of capsid inhibitors by simian immunodeficiency virus SIVcpz
260 _ _ |a Baltimore, Md.
|c 2020
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1605809954_26137
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Pandemic human immunodeficiency virus type 1 (HIV-1) is the result of the zoonotic transmission of simian immunodeficiency virus (SIV) from the chimpanzee subspecies Pan troglodytes troglodytes (SIVcpzPtt). The related subspecies Pan troglodytes schweinfurthii is the host of a similar virus, SIVcpzPts, which did not spread to humans. We tested these viruses with small-molecule capsid inhibitors (PF57, PF74, and GS-CA1) that interact with a binding groove in the capsid that is also used by CPSF6. While HIV-1 was sensitive to capsid inhibitors in cell lines, human macrophages, and peripheral blood mononuclear cells (PBMCs), SIVcpzPtt was resistant in rhesus FRhL-2 cells and human PBMCs but was sensitive to PF74 in human HOS and HeLa cells. SIVcpzPts was insensitive to PF74 in FRhL-2 cells, HeLa cells, PBMCs, and macrophages but was inhibited by PF74 in HOS cells. A truncated version of CPSF6 (CPSF6-358) inhibited SIVcpzPtt and HIV-1, while in contrast, SIVcpzPts was resistant to CPSF6-358. Homology modeling of HIV-1, SIVcpzPtt, and SIVcpzPts capsids and binding energy estimates suggest that these three viruses bind similarly to the host proteins cyclophilin A (CYPA) and CPSF6 as well as the capsid inhibitor PF74. Cyclosporine treatment, mutation of the CYPA-binding loop in the capsid, or CYPA knockout eliminated the resistance of SIVcpzPts to PF74 in HeLa cells. These experiments revealed that the antiviral capacity of PF74 is controlled by CYPA in a virus- and cell type-specific manner. Our data indicate that SIVcpz viruses can use infection pathways that escape the antiviral activity of PF74. We further suggest that the antiviral activity of PF74 capsid inhibitors depends on cellular cofactors.IMPORTANCE HIV-1 originated from SIVcpzPtt but not from the related virus SIVcpzPts, and thus, it is important to describe molecular infection by SIVcpzPts in human cells to understand the zoonosis of SIVs. Pharmacological HIV-1 capsid inhibitors (e.g., PF74) bind a capsid groove that is also a binding site for the cellular protein CPSF6. SIVcpzPts was resistant to PF74 in HeLa cells but sensitive in HOS cells, thus indicating cell line-specific resistance. Both SIVcpz viruses showed resistance to PF74 in human PBMCs. Modulating the presence of cyclophilin A or its binding to capsid in HeLa cells overcame SIVcpzPts resistance to PF74. These results indicate that early cytoplasmic infection events of SIVcpzPts may differ between cell types and affect, in an unknown manner, the antiviral activity of capsid inhibitors. Thus, capsid inhibitors depend on the activity or interaction of currently uncharacterized cellular factors.
536 _ _ |a 511 - Computational Science and Mathematical Methods (POF3-511)
|0 G:(DE-HGF)POF3-511
|c POF3-511
|f POF III
|x 0
536 _ _ |a Forschergruppe Gohlke (hkf7_20170501)
|0 G:(DE-Juel1)hkf7_20170501
|c hkf7_20170501
|f Forschergruppe Gohlke
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Scheck, Rachel
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Becker, Daniel
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Zhang, Zeli
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Wammers, Marianne
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Avelar, Leandro
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Pflieger, Marc
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Häussinger, Dieter
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Kurz, Thomas
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Gohlke, Holger
|0 P:(DE-Juel1)172663
|b 9
|u fzj
700 1 _ |a Münk, Carsten
|0 0000-0002-8026-9311
|b 10
|e Corresponding author
773 _ _ |a 10.1128/JVI.01338-20
|g p. JVI.01338-20jvi;JVI.01338-20v1
|0 PERI:(DE-600)1495529-5
|n 23
|p e01338-20
|t Journal of virology
|v 94
|y 2020
|x 1098-5514
856 4 _ |u https://juser.fz-juelich.de/record/884114/files/Journal%20of%20Virology-2020-Twizerimana-e01338-20.full.pdf
856 4 _ |y Published on 2020-11-09. Available in OpenAccess from 2021-05-09.
|u https://juser.fz-juelich.de/record/884114/files/JVI01338-20R1_Merged_PDF.pdf
856 4 _ |y Published on 2020-11-09. Available in OpenAccess from 2021-05-09.
|x pdfa
|u https://juser.fz-juelich.de/record/884114/files/JVI01338-20R1_Merged_PDF.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:884114
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)172663
913 1 _ |a DE-HGF
|b Key Technologies
|1 G:(DE-HGF)POF3-510
|0 G:(DE-HGF)POF3-511
|2 G:(DE-HGF)POF3-500
|v Computational Science and Mathematical Methods
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|l Supercomputing & Big Data
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-01-16
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J VIROL : 2018
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-16
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)JSC-20090406
|k JSC
|l Jülich Supercomputing Center
|x 0
920 1 _ |0 I:(DE-Juel1)NIC-20090406
|k NIC
|l John von Neumann - Institut für Computing
|x 1
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)JSC-20090406
980 _ _ |a I:(DE-Juel1)NIC-20090406
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21